Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies.
Author
Steele, A. M.
Wensley, K. J.
Ellard, Sian
Murphy, R.
Shepherd, Maggie
Colclough, K.
Hattersley, Andrew T.
Shields, Beverley
Date
2013Journal
PloS oneType
Observational StudyResearch Support, Non-U.S. Gov't
Publisher
PLoS OneDOI
10.1371/journal.pone.0065326Rights
Archived with thanks to PloS oneMetadata
Show full item recordAbstract
HaemoglobinA1c (HbA1c) is recommended for diabetes diagnosis but fasting plasma glucose (FPG) has been useful for identifying patients with glucokinase (GCK) mutations which cause lifelong persistent fasting hyperglycaemia. We aimed to derive age-related HbA1c reference ranges for these patients to determine how well HbA1c can discriminate patients with a GCK mutation from unaffected family members and young-onset type 1 (T1D) and type 2 diabetes (T2D) and to investigate the proportion of GCK mutation carriers diagnosed with diabetes using HbA1c and/or FPG diagnostic criteria.